Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab (OPDIVO; Bristol Myers Squibb, New York, NY) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine‐ and platinum‐based...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Pelosof, Lorraine, Saung, May Tun, Donoghue, Martha, Casak, Sandra, Mushti, Sirisha, Cheng, Joyce, Jiang, Xiling, Liu, Jiang, Zhao, Hong, Khazraee, Maryam, Goldberg, Kirsten B., Theoret, Marc, Lemery, Steven, Pazdur, Richard, Fashoyin‐Aje, Lola
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2021
Témata:
Regulatory Issues: FDA
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018317/
https://ncbi.nlm.nih.gov/pubmed/33345396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13646
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky